The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Non-Hodgkin lymphoma highlights from EHA 2025: bispecifics and CAR T-cells
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, shares his highlights in non-Hodgkin lymphoma from EHA 2025. He focuses on advancements made in the use of bispecific antibodies and CAR T-cell therapy. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are so many novelties, so many nuances. I was impressed by the evolution of bispecific antibodies and also from CAR-T because we now have bispecific antibodies that were presented in the plenary session and also dual CAR-T. That means that the bispecific antibodies directed or against two tumor antigens or a single tumor antigen but also with anti-CD3 and another costimulatory T molecule to enhance the activity of the antibodies...
There are so many novelties, so many nuances. I was impressed by the evolution of bispecific antibodies and also from CAR-T because we now have bispecific antibodies that were presented in the plenary session and also dual CAR-T. That means that the bispecific antibodies directed or against two tumor antigens or a single tumor antigen but also with anti-CD3 and another costimulatory T molecule to enhance the activity of the antibodies. And also for CAR-T yesterday there was an interesting observation of the dual CAR-T targeting CD20 CD19 that prevents antigen loss and indeed there was a small series of around 50 patients but the overall response rate was over 80% in relapsed refractory DLBCL. So what I mean is that we now have bispecific, traditional bispecific antibodies, anti-CD19, CAR-T and the future is brilliant for our patients because with the new T cell engager antibodies or CAR-T, I think that we may reduce the failures that we continue to have with bispecifics and CAR-T.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
